Skip to main content

Galectin Therapeutics Inc

GALT
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001133416

In the last 90 days, Galectin Therapeutics Inc insiders filed 0 open-market purchases and 1 sale; 98 institutions reported holding it in 13F filings for Q2 2026, worth $72.2M in total; no superinvestor holds it.

13F holders, Q2 2026

Institutional positions in Galectin Therapeutics Inc as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
98
0 vs. Q1 2026
Shares held
15.6M
+1.69M (+12.1%) vs. Q1 2026
Total value
$72.2M
+$33.4M (+86.3%) vs. Q1 2026
New holders
20
32 more added
Sold out
20
23 more reduced

1 institution that held it in Q1 2026 haven't filed for Q2 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.

Compare with Q1 2026: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting GALT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ2 2026: 98 institutions
Q1 2021: 75 institutionsQ2 2021: 75 institutionsQ3 2021: 70 institutionsQ4 2021: 55 institutionsQ1 2022: 60 institutionsQ2 2022: 60 institutionsQ3 2022: 59 institutionsQ4 2022: 61 institutionsQ1 2023: 60 institutionsQ2 2023: 60 institutionsQ3 2023: 60 institutionsQ4 2023: 66 institutionsQ1 2024: 59 institutionsQ2 2024: 73 institutionsQ3 2024: 79 institutionsQ4 2024: 94 institutionsQ1 2025: 93 institutionsQ2 2025: 86 institutionsQ3 2025: 84 institutionsQ4 2025: 98 institutionsQ1 2026: 99 institutionsQ2 2026: 98 institutions
Value heldQ2 2026: $72.2M
Q1 2021: $22.7MQ2 2021: $25.3MQ3 2021: $28.2MQ4 2021: $15.2MQ1 2022: $12.0MQ2 2022: $9.25MQ3 2022: $11.3MQ4 2022: $8.04MQ1 2023: $15.0MQ2 2023: $10.5MQ3 2023: $17.4MQ4 2023: $12.0MQ1 2024: $18.2MQ2 2024: $21.6MQ3 2024: $26.8MQ4 2024: $13.0MQ1 2025: $12.2MQ2 2025: $22.2MQ3 2025: $43.9MQ4 2025: $48.1MQ1 2026: $38.8MQ2 2026: $72.2M
Institutions holding GALT and their total value by quarter
QuarterHoldersValue
Q2 202698$72.2M
Q1 202699$38.8M
Q4 202598$48.1M
Q3 202584$43.9M
Q2 202586$22.2M
Q1 202593$12.2M
Q4 202494$13.0M
Q3 202479$26.8M
Q2 202473$21.6M
Q1 202459$18.2M
Q4 202366$12.0M
Q3 202360$17.4M
Q2 202360$10.5M
Q1 202360$15.0M
Q4 202261$8.04M
Q3 202259$11.3M
Q2 202260$9.25M
Q1 202260$12.0M
Q4 202155$15.2M
Q3 202170$28.2M
Q2 202175$25.3M
Q1 202175$22.7M

Institutions, Q2 2026

Shares, value and share of portfolio for each institution holding Galectin Therapeutics Inc; share changes are against Q1 2026.

Institutions holding GALT in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
683 Capital Management, LLC0$00.00%−162,484−100.0%Sold out
Qube Research & Technologies Ltd0$00.00%−126,439−100.0%Sold out
Hudson Bay Capital Management LP0$00.00%−74,728−100.0%Sold out
HRT Financial LP0$00.00%−51,058−100.0%Sold out
Wiley Bros.-Aintree Capital, LLC0$00.00%−41,000−100.0%Sold out
Brevan Howard Capital Management LP0$00.00%−35,585−100.0%Sold out
Omers Administration Corp0$00.00%−24,100−100.0%Sold out
Catalyst Funds Management Pty Ltd0$00.00%−22,500−100.0%Sold out
Nine Masts Capital Ltd0$00.00%−19,324−100.0%Sold out
Engineers Gate Manager LP0$00.00%−18,739−100.0%Sold out
Diametric Capital, LP0$00.00%−17,089−100.0%Sold out
Colony Group, LLC0$00.00%−13,897−100.0%Sold out
Jefferies Financial Group Inc.0$00.00%−12,188−100.0%Sold out
Mercer Global Advisors Inc0$00.00%−10,113−100.0%Sold out
Sound Income Strategies, LLC0$00.00%−2,980−100.0%Sold out
MAI Capital Management0$00.00%−1,000−100.0%Sold out
Hamrick Investment Counsel, llc0$00.00%−100−100.0%Sold out
True Wealth Design, LLC0$00.00%−2−100.0%Sold out
CWM, LLC––––Not filed